Skip to main content
Log in

Clinical applicability of current pharmacokinetic models: Splanchnic elimination of 5-fluorouracil in cancer patients

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

What can be inferred from limited clinical data by using current models of hepatic elimination? We examined this question by analyzing previously published data on the steady-state uptake of the anticancer agent 5-fluorouracil (5-FU) in seven cancer patients in terms of the venous equilibration model, the undistributed and distributed forms of the sinusoidal perfusion model, and the convection-dispersion model. Because of appreciable extrasplanchnic removal of 5-FU, the value of the steady infusion rate was not used in our analysis. When the data from all patients were pooled by plotting the measured hepatic venous concentration against the measured hepatic arterial concentration, the high concentration data fell on a limiting straight line of slope 1, indicating that at high dose rates elimination of 5-FU in both the liver and gastrointestinal tract was close to saturation. The intercept of this line gave a model-independent estimate of Vmax/Q= 48.0±11.6 (SD) μM for the pooled data set, where Vmax is the maximum splanchnic elimination rate of 5-FU, and Q is the hepatic blood flow. The low concentration data points fell on a limiting straight line through the origin, from which model-dependent values of the Michaelis constant were determined. The venous equilibration model gave K m=9.4μM,while the undistributed sinusoidal perfusion model gave K *m =26,5μM. With these values of K m,both models fit the pooled data equally well. These methods were applied to analyses of the five individual data sets which contained sufficiently high concentration data points. The resulting mean values were Vmax/Q=41.0±5.1 (sem) μM,K m=8.4±1.3μM and K *m =23.2±3.2 μM. However, the splanchnic region is a highly heterogeneous organ system, for which an undistributed analysis provides no more than an upper bound on the Michaelis constant K +m (K +m K *m ).A perfusion model distributed to represent total splanchnic elimination is developed in the Appendix. Using previous estimates of the degree of functional heterogeneity in the liver alone, this model yields K +m values for individual patients which have a mean of 20.3±2.8 μM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. J. L. Speyer, P. H. Sugarbaker, J. M. Collins, R. L. Dedrick, R. W. Klecker, Jr., and C. E. Myers. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.Cancer Res. 41:1916–1922 (1981).

    CAS  PubMed  Google Scholar 

  2. M. Chadwick and J. Rogers. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.Cancer Res. 32:1045–1056 (1972).

    CAS  PubMed  Google Scholar 

  3. B. G. Gustavsson, A. Brandberg, C. G. Regardh, and O. E. Almersjo. Regional and systemic serum concentration of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs.J. Pharmacokin. Biopharm. 7:665–673 (1979).

    Article  CAS  Google Scholar 

  4. Y.-H. Kao, C.-Y. Yang, R. R. L. Chen, and J.-D. Huang. Pulmonary elimination of 5-fluorouracil in anesthetized rats.J. Pharm. Sci. 74:1095–1096 (1985).

    Article  CAS  PubMed  Google Scholar 

  5. J. G. Wagner, J. W. Gyves, P. L. Stetson, S. C. Walker-Andrews, I. S. Wollner, M. K. Cochran, and W. P. Ensminger. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.Cancer Res. 46:1499–1506 (1986).

    CAS  PubMed  Google Scholar 

  6. L. Bass, S. Keiding, K. Winkler, and N. Tygstrup. Enzymatic elimination of substrates flowing through the intact liver.J. Theor. Biol. 61:393–409 (1976).

    Article  CAS  PubMed  Google Scholar 

  7. J. R. Gillette. Factors affecting drug metabolism.Ann. N.Y. Acad. Sci. 179:43–66 (1971).

    Article  CAS  PubMed  Google Scholar 

  8. M. Rowland, L. Z. Benet, and G. G. Graham. Clearance concepts in pharmacokinetics.J. Pharmacokin. Biopharm. 20:123–136 (1973).

    Article  Google Scholar 

  9. R. A. Branch, A. S. Nies, and D. G. Shand. The disposition of propranolol VIII. General implications of the effects of liver blood flow on elimination from the perfused rat liver.Drug Metab. Dispos. 1:687–690 (1973).

    CAS  PubMed  Google Scholar 

  10. L. Bass, P. J. Robinson, and A. J. Bracken. Hepatic elimination of flowing substrates: The distributed model.J. Theor. Biol. 72:161–184 (1978).

    Article  CAS  PubMed  Google Scholar 

  11. M. S. Roberts and M. Rowland. Hepatic elimination—dispersion model.J. Pharm. Sci. 74:585–587 (1985).

    Article  CAS  PubMed  Google Scholar 

  12. M. S. Roberts and M. Rowland. A dispersion model of hepatic elimination.J. Pharmacokin. Biopharm. 14:227–308 (1986).

    Article  CAS  Google Scholar 

  13. L. Bass, M. S. Roberts, and P. J. Robinson. On the relation between extended forms of the sinusoidal perfusion and of the convection-dispersion models of hepatic elimination.J. Theor. Biol 126:457–482 (1987).

    Article  CAS  PubMed  Google Scholar 

  14. R. W. Brauer, G. F. Leong, R. F. McElroy, and R. J. Holloway. Circulatory pathways in the rat liver as revealed by P32 chromic phosphate colloid uptake in the isolated perfused liver preparation.Am. J. Physiol. 184:593–598 (1956).

    CAS  PubMed  Google Scholar 

  15. L. Bass. Flow-dependence of first-order uptake of substances by heterogeneous perfused organs.J. Theor. Biol. 86:365–376 (1980).

    Article  CAS  PubMed  Google Scholar 

  16. K. S. Pang and M. Rowland. Hepatic clearance of drugs. II. Experimental evidences for acceptance of the “well stirred” model over the “parallel tube” model using lidocaine in the perfused rat liver insitu preparation.J. Pharmacokin. Biopharm. 5:655–680 (1977).

    Article  CAS  Google Scholar 

  17. S. Keiding and E. Chiarantini. Effect of sinusoidal perfusion on galactose elimination kinetics in perfused rat liver.J. Pharmacol. Exp. Ther. 205:465–470 (1978).

    CAS  PubMed  Google Scholar 

  18. S. Keiding and E. Steiness. Flow dependence of propranolol elimination in perfused rat liver.J. Pharmacol. Exp. Ther. 230:474–477 (1984).

    CAS  PubMed  Google Scholar 

  19. L. Bass. Saturation kinetics in hepatic drug removal: a statistical approach to functional heterogeneity.Am. J. Physiol. 244:G583-G589 (1983).

    CAS  PubMed  Google Scholar 

  20. L. Bass and P. J. Robinson. Effects of capillary heterogeneity on rates of steady uptake of substances by the intact liver.Microvasc. Res. 22:43–57 (1981).

    Article  CAS  PubMed  Google Scholar 

  21. F. Mentre, J. L. Steimer, J. P. Sommadossi, R. B. Diasio, and J. P. Cano. A mathematical model of the kinetics of 5-fluorouracil and its catabolites in freshly isolated rat hepatocytes.Biochem. Pharmacol. 33:2727–2732 (1984).

    Article  CAS  PubMed  Google Scholar 

  22. J. M. Pries, A. B. Staples, and R. F. Hanson. Effect of hepatic blood flow on taurocholate extraction by the isolated perfused rat liver.J. Lab. Clin. Med. 97:412–417 (1981).

    CAS  PubMed  Google Scholar 

  23. L. Bass and P. J. Robinson. How small is the functional variability of liver sinusoids?J. Theor. Biol. 81:761–769 (1979).

    Article  CAS  PubMed  Google Scholar 

  24. S. Keiding, S. Johansen, K. Winkler, K. Tonnesen, and N. Tygstrup. Michaelis-Menten kinetics of galactose elimination by the isolated pig liver.Am. J. Physiol. 230:1302–1313 (1976).

    CAS  PubMed  Google Scholar 

  25. P. J. Robinson. Aspects of mathematical liver kinetics: the steady-state statistical mechanics of hepatic elimination. Ph.D. thesis, University of Queensland. (University Microfilms International, Ann Arbor, Michigan, 1979)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

We are grateful to the Australian Research Grants Scheme and the National Health and Medical Research Council for financial support, and to the Department of Science for the award of a National Research Fellowship to P.J.R.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, P.J., Bass, L., Pond, S.M. et al. Clinical applicability of current pharmacokinetic models: Splanchnic elimination of 5-fluorouracil in cancer patients. Journal of Pharmacokinetics and Biopharmaceutics 16, 229–249 (1988). https://doi.org/10.1007/BF01062135

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01062135

Key words

Navigation